Nevertheless, we do agree that biotech companies, and to some extent wearable technologies -- which monitor our vitals, raise unique ethical concerns that need to be addressed. For example, direct to consumer personal genomic companies raise unique privacy concerns given that genetic information obtained by the consumer overlaps significantly with that of their relatives. However, while IRBs have their place in the ivory tower of basic science research, commercial entities are not shielded from regulatory bodies such as the FDA or various market forces that otherwise tend to do a good job weeding out the dangerous or bad actors.
Dov Greenbaum & Mark Gerstein
Unpublished letter in response to:
"The Ethics of Experimenting on Yourself" by Amy Dockser Marcus
Wall St. Journal